MCID: LPN002
MIFTS: 60

Lip and Oral Cavity Cancer

Categories: Cancer diseases, Oral diseases, Rare diseases, Smell/Taste diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Lip and Oral Cavity Cancer

MalaCards integrated aliases for Lip and Oral Cavity Cancer:

Name: Lip and Oral Cavity Cancer 19
Oral Cancer 19 53 41 2 75
Lip and Oral Cavity Carcinoma 5 71
Malignant Neoplasm of Mouth 71

Classifications:



External Ids:

ICD10 31 C06.9
UMLS 71 C0153381 C0220641

Summaries for Lip and Oral Cavity Cancer

CDC: 2 In 2012, there were nearly 40,000 new cases of cancer of the oral cavity and pharynx diagnosed in the United States and nearly 9,000 deaths. The 5-year survival rate for these cancers is about 59 percent. Mortality from oral cancer is nearly twice as high in some minorities (especially black males) as it is in whites. Preventing high risk behaviors, that include cigarette, cigar or pipe smoking, use of smokeless tobacco, and excessive use of alcohol are critical in preventing oral cancers. Early detection is key to increasing the survival rate for these cancers. Oral Human Papilloma Virus (HPV), the most common sexually transmitted disease, can cause cancers in the back of the throat, called "oropharyngeal cancers." More research is needed to determine whether HPV itself causes oropharyngeal cancers, or if other factors (such as smoking or chewing tobacco) interact with HPV to cause these cancers.

MalaCards based summary: Lip and Oral Cavity Cancer, also known as oral cancer, is related to leukoplakia and oral submucous fibrosis, and has symptoms including snoring and halitosis. An important gene associated with Lip and Oral Cavity Cancer is TP53 (Tumor Protein P53), and among its related pathways/superpathways are Disease and Signal Transduction. The drugs Dopamine and Racepinephrine have been mentioned in the context of this disorder. Affiliated tissues include tongue, lymph node and endothelial, and related phenotypes are Decreased viability and Decreased substrate adherent cell growth

MedlinePlus: 41 Oral cancer can form in any part of the mouth. Most oral cancers begin in the flat cells that cover the surfaces of your mouth, tongue, and lips. Anyone can get oral cancer, but the risk is higher if you are male, use tobacco, drink lots of alcohol, have HPV, or have a history of head or neck cancer. Frequent sun exposure is also a risk factor for lip cancer. Symptoms of oral cancer include : White or red patches in your mouth A mouth sore that won't heal Bleeding in your mouth Loose teeth Problems or pain with swallowing A lump in your neck An earache Tests to diagnose oral cancer include a physical exam, endoscopy, biopsy, and imaging tests. Oral cancer treatments may include surgery, radiation therapy, and chemotherapy. Some patients have a combination of treatments. NIH: National Cancer Institute

GARD: 19 A carcinoma arising in the lip or oral cavity. Most oral cavity carcinomas are squamous cell carcinomas of the tongue, buccal mucosa, or gums. Less frequent morphologic variants include mucoepidermoid carcinoma and adenocarcinoma. Lip carcinomas are usually basal cell or squamous cell carcinomas.

Wikipedia: 75 Oral cancer, also known as mouth cancer, is cancer of the lining of the lips, mouth, or upper throat. In... more...

Related Diseases for Lip and Oral Cavity Cancer

Diseases related to Lip and Oral Cavity Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 731)
# Related Disease Score Top Affiliating Genes
1 leukoplakia 31.6 KRT13 GSTM1 CYP1A1
2 oral submucous fibrosis 31.2 TP53 MIR21 EGFR CYP1A1
3 lichen planus 31.2 TP53 MIR31 KRT13
4 head and neck cancer 31.2 TP53 PIK3CA MIR31 MIR21 HRAS EGFR
5 lip cancer 31.0 TP53 MIR345 CDKN2A
6 papilloma 31.0 TP53 RB1 KRT13 EGFR CDKN2A CCND1
7 tongue carcinoma 31.0 TP53 RB1 MIR31 MIR21 EGFR CDKN2A
8 verrucous carcinoma 30.9 TP53 PIK3CA EGFR CDKN2A
9 oropharynx cancer 30.8 TP53 PIK3CA MIR21 KIT HRAS EGFR
10 squamous cell carcinoma 30.6 TP53 STK11 RB1 PIK3CA KRT13 HRAS
11 exanthem 30.6 KIT HRAS EGFR
12 ataxia-telangiectasia 30.5 TP53 STK11 BRAF ABL1
13 keratoacanthoma 30.5 TP53 PIK3CA EGFR
14 salivary gland carcinoma 30.4 TP53 KIT EGFR CDKN2A
15 retinoblastoma 30.4 TP53 RB1 CDKN2A CCND1 ABL1
16 sarcoma 30.3 TP53 RB1 PIK3CA KIT HRAS BRAF
17 laryngeal benign neoplasm 30.3 TP53 PIK3CA EGFR CDKN2A CCND1
18 suppressor of tumorigenicity 3 30.3 TP53 RB1 CDKN2A
19 familial adenomatous polyposis 30.3 TP53 HRAS CCND1 BRAF
20 squamous cell carcinoma, head and neck 30.3 TP53 RB1 RARB PIK3CA MIR31 MIR21
21 basaloid squamous cell carcinoma 30.3 TP53 KIT CDKN2A
22 anogenital venereal wart 30.3 TP53 RB1 CDKN2A
23 keratosis 30.3 TP53 PIK3CA HRAS EGFR CDKN2A
24 basal cell carcinoma 30.2 TP53 GSTM1 EGFR CYP1A1 CDKN2A
25 larynx cancer 30.2 TP53 MIR31 MIR21 GSTM1 EGFR CCND1
26 b-lymphoblastic leukemia/lymphoma 30.1 KIT CDKN2A ABL1
27 leukemia 30.1 TP53 KIT CDKN2A CCND1 BRAF ABL1
28 myoma 30.0 TP53 KIT EGFR
29 nasopharyngeal carcinoma 30.0 TP53 PIK3CA MIR31 MIR21 GSTM1 EGFR
30 adenoid cystic carcinoma 30.0 TP53 PIK3CA LRRC56 KIT HRAS EGFR
31 lipomatosis, multiple 30.0 TP53 PIK3CA KIT
32 skin carcinoma 30.0 TP53 MIR31 MIR21 KIT HRAS EGFR
33 inherited cancer-predisposing syndrome 29.9 TP53 STK11 RB1 KIT EGFR CDKN2A
34 bap1 tumor predisposition syndrome 29.9 TP53 STK11 RB1 KIT EGFR CDKN2A
35 leukemia, chronic myeloid 29.9 TP53 KIT HRAS EGFR CCND1 BRAF
36 hypopharynx cancer 29.9 TP53 EGFR CDKN2A CCND1
37 skin melanoma 29.9 TP53 PIK3CA MIR21 LRRC56 KIT HRAS
38 female breast cancer 29.9 TP53 EGFR CDKN2A CCND1
39 human papillomavirus infectious disease 29.8 TP53 PIK3CA MIR31 MIR21 KRT13 HRAS
40 adenocarcinoma 29.8 TP53 STK11 RB1 PIK3CA HRAS EGFR
41 li-fraumeni syndrome 29.8 TP53 STK11 RB1 PIK3CA HRAS EGFR
42 kidney cancer 29.7 TP53 PIK3CA MIR21 EGFR CDKN2A
43 anus cancer 29.7 TP53 RB1 PIK3CA HRAS EGFR CDKN2A
44 laryngeal squamous cell carcinoma 29.7 TP53 MIR21 GSTM1 EGFR CYP1A1 CDKN2A
45 cervical squamous cell carcinoma 29.7 TP53 PIK3CA EGFR CDKN2A CCND1
46 adenoma 29.7 TP53 PIK3CA HRAS CDKN2A CCND1 BRAF
47 acute promyelocytic leukemia 29.7 TP53 RARB PIK3CA KIT HRAS CCND1
48 hematologic cancer 29.7 RB1 MIR31 MIR21 KIT HRAS ABL1
49 wilms tumor 1 29.7 TP53 KIT HRAS EGFR CDKN2A CCND1
50 tonsil cancer 29.6 TP53 PIK3CA KIT EGFR CDKN2A CCND1

Graphical network of the top 20 diseases related to Lip and Oral Cavity Cancer:



Diseases related to Lip and Oral Cavity Cancer

Symptoms & Phenotypes for Lip and Oral Cavity Cancer

UMLS symptoms related to Lip and Oral Cavity Cancer:


snoring; halitosis

GenomeRNAi Phenotypes related to Lip and Oral Cavity Cancer according to GeneCards Suite gene sharing:

25 (show all 41)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 10.69 BRAF EGFR HRAS PIK3CA
2 Decreased viability GR00055-A-2 10.69 BRAF EGFR HRAS PIK3CA
3 Decreased viability GR00221-A-1 10.69 EGFR HRAS PIK3CA ABL1 CDKN2A KIT
4 Decreased viability GR00221-A-2 10.69 HRAS PIK3CA ABL1
5 Decreased viability GR00221-A-3 10.69 HRAS ABL1 CDKN2A
6 Decreased viability GR00221-A-4 10.69 BRAF EGFR PIK3CA CDKN2A
7 Decreased viability GR00249-S 10.69 BRAF
8 Decreased viability GR00301-A 10.69 BRAF KIT
9 Decreased viability GR00342-S-1 10.69 ABL1
10 Decreased viability GR00342-S-2 10.69 ABL1
11 Decreased viability GR00342-S-3 10.69 ABL1
12 Decreased viability GR00381-A-1 10.69 BRAF
13 Decreased viability GR00402-S-2 10.69 PIK3CA
14 Decreased substrate adherent cell growth GR00193-A-1 9.8 KIT
15 Decreased substrate adherent cell growth GR00193-A-2 9.8 ABL1 KIT
16 Decreased substrate adherent cell growth GR00193-A-3 9.8 BRAF
17 Decreased substrate adherent cell growth GR00193-A-4 9.8 ABL1 BRAF KIT
18 Increased shRNA abundance (Z-score > 2) GR00366-A-10 9.77 RARB
19 Increased shRNA abundance (Z-score > 2) GR00366-A-151 9.77 ABL1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.77 KIT
21 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.77 ABL1 KIT
22 Increased shRNA abundance (Z-score > 2) GR00366-A-165 9.77 KRT13
23 Increased shRNA abundance (Z-score > 2) GR00366-A-170 9.77 KIT
24 Increased shRNA abundance (Z-score > 2) GR00366-A-184 9.77 RARB
25 Increased shRNA abundance (Z-score > 2) GR00366-A-189 9.77 KRT13
26 Increased shRNA abundance (Z-score > 2) GR00366-A-21 9.77 KRT13
27 Increased shRNA abundance (Z-score > 2) GR00366-A-211 9.77 KRT13
28 Increased shRNA abundance (Z-score > 2) GR00366-A-213 9.77 ABL1 RARB
29 Increased shRNA abundance (Z-score > 2) GR00366-A-23 9.77 RARB
30 Increased shRNA abundance (Z-score > 2) GR00366-A-30 9.77 ABL1 KIT
31 Increased shRNA abundance (Z-score > 2) GR00366-A-33 9.77 KRT13
32 Increased shRNA abundance (Z-score > 2) GR00366-A-34 9.77 ABL1 KRT13 RARB
33 Increased shRNA abundance (Z-score > 2) GR00366-A-43 9.77 ABL1
34 Increased shRNA abundance (Z-score > 2) GR00366-A-47 9.77 ABL1
35 Increased shRNA abundance (Z-score > 2) GR00366-A-61 9.77 KIT
36 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.77 KRT13
37 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.77 ABL1 KIT
38 Increased shRNA abundance (Z-score > 2) GR00366-A-9 9.77 KIT
39 Increased shRNA abundance (Z-score > 2) GR00366-A-99 9.77 KIT
40 Increased cell viability after pRB stimulation GR00230-A-1 9.46 ABL1 EGFR KIT STK11
41 Decreased viability in pancreas lineage GR00235-A 9.13 CCND1 RARB TP53

MGI Mouse Phenotypes related to Lip and Oral Cavity Cancer:

45 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.44 ABL1 BRAF CCND1 CDK2AP1 CDKN2A CYP1A1
2 nervous system MP:0003631 10.4 ABL1 BRAF CCND1 CDKN2A EGFR GSTM1
3 homeostasis/metabolism MP:0005376 10.4 ABL1 BRAF CCND1 CDKN2A CYP1A1 EGFR
4 endocrine/exocrine gland MP:0005379 10.37 ABL1 BRAF CCND1 CDKN2A CYP1A1 EGFR
5 neoplasm MP:0002006 10.35 BRAF CCND1 CDKN2A EGFR HRAS KIT
6 normal MP:0002873 10.35 ABL1 BRAF CCND1 CYP1A1 EGFR HRAS
7 muscle MP:0005369 10.32 ABL1 BRAF CDKN2A EGFR HRAS KIT
8 digestive/alimentary MP:0005381 10.31 ABL1 BRAF CCND1 CDKN2A EGFR HRAS
9 cellular MP:0005384 10.27 ABL1 BRAF CCND1 CDK2AP1 CDKN2A EGFR
10 craniofacial MP:0005382 10.26 ABL1 BRAF CCND1 CDK2AP1 EGFR HRAS
11 no phenotypic analysis MP:0003012 10.25 CDKN2A CYP1A1 EGFR HRAS KIT PIK3CA
12 embryo MP:0005380 10.25 ABL1 BRAF CDK2AP1 CDKN2A EGFR KIT
13 cardiovascular system MP:0005385 10.25 ABL1 BRAF CCND1 CDKN2A EGFR HRAS
14 liver/biliary system MP:0005370 10.22 ABL1 BRAF CDKN2A CYP1A1 EGFR KIT
15 immune system MP:0005387 10.22 ABL1 BRAF CCND1 CDKN2A CYP1A1 EGFR
16 renal/urinary system MP:0005367 10.19 BRAF EGFR HRAS KIT RARB RB1
17 respiratory system MP:0005388 10.15 ABL1 BRAF CCND1 CDKN2A EGFR HRAS
18 reproductive system MP:0005389 10.1 BRAF CCND1 CDKN2A EGFR KIT LRRC56
19 pigmentation MP:0001186 10.09 BRAF CDKN2A EGFR KIT RB1 TP53
20 hearing/vestibular/ear MP:0005377 10.09 BRAF EGFR GSTM1 KIT RARB RB1
21 skeleton MP:0005390 10.03 ABL1 BRAF CCND1 CDKN2A EGFR HRAS
22 vision/eye MP:0005391 9.9 ABL1 BRAF CCND1 CDKN2A EGFR KIT
23 mortality/aging MP:0010768 9.86 ABL1 BRAF CCND1 CDK2AP1 CDKN2A CYP1A1
24 integument MP:0010771 9.4 BRAF CCND1 CDKN2A EGFR HRAS KIT

Drugs & Therapeutics for Lip and Oral Cavity Cancer

Drugs for Lip and Oral Cavity Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 161)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 62-31-7, 51-61-6 681
2
Racepinephrine Approved, Vet_approved Phase 4 51-43-4, 329-65-7 838 5816
3
Dopexamine Approved, Investigational Phase 4 86197-47-9 55483
4
Norepinephrine Approved Phase 4 51-41-2 439260
5
Dobutamine Approved Phase 4 34368-04-2 36811
6 Dopamine Agents Phase 4
7 Epinephryl borate Phase 4
8 Cardiotonic Agents Phase 4
9 Bronchodilator Agents Phase 4
10 Adrenergic beta-Agonists Phase 4
11 Adrenergic alpha-Agonists Phase 4
12 Anti-Asthmatic Agents Phase 4
13 Adrenergic Agonists Phase 4
14 Adrenergic Agents Phase 4
15 Dopamine agonists Phase 4
16 Vasodilator Agents Phase 4
17 Vasoconstrictor Agents Phase 4
18 Respiratory System Agents Phase 4
19 Mydriatics Phase 4
20 Sympathomimetics Phase 4
21
Erlotinib Approved, Investigational Phase 3 183319-69-9, 183321-74-6 176870
22
Zinc cation Approved, Experimental, Investigational Phase 3 7440-66-6, 23713-49-7 32051
23
Zinc sulfate Approved, Investigational Phase 3 7733-02-0
24
Docetaxel Approved, Investigational Phase 2, Phase 3 114977-28-5 148124
25
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904
26
Atezolizumab Approved, Investigational Phase 2, Phase 3 1380723-44-3
27
Cetuximab Approved Phase 2, Phase 3 205923-56-4
28
Durvalumab Approved, Investigational Phase 2, Phase 3 1428935-60-7
29 Trace Elements Phase 3
30 Micronutrients Phase 3
31 Antimitotic Agents Phase 2, Phase 3
32 Tubulin Modulators Phase 2, Phase 3
33 Antineoplastic Agents, Immunological Phase 2, Phase 3
34 Immunoglobulins, Intravenous Phase 2, Phase 3
35 Immunoglobulins Phase 2, Phase 3
36 Immunoglobulin G Phase 2, Phase 3
37 Antibodies, Monoclonal Phase 2, Phase 3
38 Antibodies Phase 2, Phase 3
39
Plasminogen Approved Phase 2 9001-91-6
40
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
41 Raspberry Approved Phase 1, Phase 2
42
Aminolevulinic acid Approved Phase 1, Phase 2 106-60-5 137
43 Orange Approved Phase 1, Phase 2
44
Hydroxyurea Approved Phase 1, Phase 2 127-07-1 3657
45
Pembrolizumab Approved Phase 2 1374853-91-4 254741536
46
Nivolumab Approved Phase 2 946414-94-4
47
Cemiplimab Approved, Investigational Phase 2 1801342-60-8
48
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
49
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
50
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703

Interventional clinical trials:

(show top 50) (show all 173)
# Name Status NCT ID Phase Drugs
1 Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions: A Randomised Clinical Trial Unknown status NCT03684707 Phase 4 Metformin Hcl 500Mg 24Hr Sa Tab
2 An Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery: A Randomised Study Completed NCT01418118 Phase 4 Epinephrine;Norepinephrine;Dobutamine;Dopexamine
3 The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor Recruiting NCT03017053 Phase 4
4 Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions: A Randomized Clinical Trial (Part 1) Unknown status NCT03685409 Phase 3 Metformin Hydrochloride 500 MG;Placebo Oral Tablet
5 Comparing the Test Characteristics of Three Oral Cancer Screening Techniques:1)Unaided Visual Examination 2)VelScope Examination and 3)Toluidine Blue Application, by Trained Primary Health Care Workers in Mumbai, India. Unknown status NCT00655421 Phase 3
6 Canadian Optically Guided Approach for Oral Lesions Surgical Trial - COOLS Unknown status NCT01039298 Phase 3
7 Workplace Tobacco Cessation And Oral Cancer Screening Study Completed NCT00750503 Phase 3
8 Erlotinib Prevention of Oral Cancer (EPOC) Completed NCT00402779 Phase 3 Erlotinib;Placebo
9 Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma Completed NCT00158652 Phase 3 5FU, Paraplatin
10 Effectiveness of Adjuvant Radiotherapy in Patients With Oropharyngeal and Floor of Mouth Squamous Cell Carcinoma and Concomitant Histological Verification of Singular Ipsilateral Cervical Lymph Node Metastasis (pN1-state) Completed NCT00964977 Phase 3
11 Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma Completed NCT00158678 Phase 3 concomitant cisplatin
12 A Randomized Trial Evaluating a Very Intense Radiotherapy-Chemotherapy Regimen Versus a Very Accelerated Radiotherapy in Advanced Head and Neck Squamous Cell Carcinoma Completed NCT00162708 Phase 2, Phase 3 CDDP, 5 Fu
13 Neoadjuvant Erbitux Based Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01434394 Phase 2, Phase 3 Neo-adjuvant Erbitux-based chemotherapy
14 Efficacy of Zinc Sulfate on Concurrent Chemoradiotherapy Induced Taste Alterations in Oral Cancer Patients- A Double Blind Randomized Controlled Trial Completed NCT03824925 Phase 3 Placebo oral Zinc capsule;Zinc Sulfate 220 MG
15 A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers Recruiting NCT05063552 Phase 2, Phase 3 Carboplatin;Cisplatin;Docetaxel
16 Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer Recruiting NCT04333537 Phase 2, Phase 3 Imaging Agent
17 Randomized Phase II/III Trial of Radiotherapy With Concurrent MEDI4736 (Durvalumab) vs. Radiotherapy With Concurrent Cetuximab in Patients With Locoregionally Advanced Head and Neck Cancer With a Contraindication to Cisplatin Active, not recruiting NCT03258554 Phase 2, Phase 3
18 Virtual Preplanning of Mandibular Reconstruction (ViPMR): a Phase III Randomized Controlled Clinical Trial Not yet recruiting NCT05429099 Phase 2, Phase 3
19 Evaluation of OraTest in Combination With Visual Examination in the Improved Detection of Oral Mucosal Lesions Suspicious of Serious Pathology in High-Risk Patients for the Purpose of Referral to the Health Care Professional Experienced in Oral Cancer: Phase III Clinical Trial Comparing the Sensitivity and Assessing the Specificity of OraTest in Combination With Visual Examination and Visual Examination Alone in Patients at High Risk as Defined by Age and Lifestyle Factors (ZIL-401) Terminated NCT00537199 Phase 3 OraTest
20 Phase II Trial: uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer Unknown status NCT02960724 Phase 2
21 Phrase II Single Arm Study of Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral Unknown status NCT03008694 Phase 2
22 Development of Novel Diagnostic Tools and Therapeutic Strategies for Oral Cancer Unknown status NCT02739204 Phase 2 Celecoxib
23 Evaluation of Photobiomodumation Using LED Lamp as a Curative Treatment for Oral or Oropharyngeal Mucositic Inducted by Radiation Therapy Completed NCT04251949 Phase 2
24 A Phase II Study of Neoadjuvant Bio-chemotherapy With Cetuximab, Paclitaxel, and Cisplatin (CPC) Followed by Cetuximab-based Concurrent Bio-radiotherapy in High-risk Locally Advanced Oral Squamous Cell Carcinoma (OSCC) Completed NCT00933387 Phase 2 Cetuximab,Paclitaxel,Cisplatin
25 Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Completed NCT03638622 Phase 1, Phase 2
26 Randomised Pilot Study of Therabite® Versus Wooden Spatula in the Amelioration of Trismus in Head and Neck Cancer Patients. (Trismus Trial) Completed NCT01733797 Phase 2
27 A Study of the Effects of PEITC on Oral Cells With Mutant p53 Completed NCT01790204 Phase 1, Phase 2
28 Neo-adjuvant Erbitux-based Chemotherapy Followed by Surgery and Radiotherapy for Locally Advanced Oral/Oropharyngeal Cancer Completed NCT01440270 Phase 2 Neo-adjuvant Erbitux-based chemotherapy
29 A Phase I Study of Concomitant Chemoradiotherapy With 776C85, 5-FU and Hydroxyurea for Patients With Poor Prognosis Oral Cancer Completed NCT00004901 Phase 1, Phase 2 ethynyluracil;fluorouracil;hydroxyurea
30 Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention Completed NCT01192204 Phase 1, Phase 2 10% FBR containing bioadhesive gel;placebo gel
31 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention
32 Clinical Protocol for Wild Type p53 Gene Induction in Premalignancies of Squamous Epithelium of the Oral Cavity and Oral Pharynx Via an Adenoviral Vector [NCI Supplied Agent Ad-p53, (INGN 201) (Advexin®) NSC 683550, IND# 7135] Completed NCT00064103 Phase 1, Phase 2
33 Bowman Birk Inhibitor Concentrate and Oral Leukoplakia: A Randomized Phase IIb Trial Completed NCT00330382 Phase 2 Bowman-Birk inhibitor concentrate
34 Phase 1-2 18F-FPPRGD2 PET/CT or PET/MRI Imaging of αvβ3 Integrins Expression as a Biomarker of Angiogenesis Completed NCT01806675 Phase 1, Phase 2 18F-fludeoxyglucose (18F-FDG);18F-FPPRGD2
35 Phase II Randomized Trial of Radiotherapy With Concurrent and Adjuvant Pembrolizumab (Keytruda®) Versus Concurrent Chemotherapy in Patients With Advanced/Intermediate-Risk p16+ Head and Neck Squamous Cell Carcinoma (KEYCHAIN) Recruiting NCT03383094 Phase 2 Pembrolizumab;Cisplatin
36 A Phase II Trial of the Efficacy and Safety of the Combination of Cemiplimab and Low-Dose Paclitaxel and Carboplatin in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Recruiting NCT04862650 Phase 2 Carboplatin;Paclitaxel
37 Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing Recruiting NCT02734537 Phase 2 Cisplatin
38 Biomarker Stratified CaboZantinib (NSC#761968) and NivOlumab (NSC#748726) (BiCaZO) - A Phase II Study of Combining Cabozantinib and Nivolumab in Patients With Advanced Solid Tumors (IO Refractory Melanoma or HNSCC) Stratified by Tumor Biomarkers - an immunoMATCH Pilot Study Recruiting NCT05136196 Phase 2 Cabozantinib S-malate
39 Multimodality Therapy With Induction Carboplatin/Nab-Paclitaxel/Durvalumab Followed by Surgical Resection and Risk-adapted Adjuvant Therapy for the Treatment of Locally-Advanced and Surgically Resectable Squamous Cell Carcinoma of the Head and Neck Active, not recruiting NCT03174275 Phase 2 Durvalumab;Carboplatin;Nab-paclitaxel;Cisplatin
40 A Phase II Study of Durvalumab (MEDI 4736) With Radiotherapy for the Adjuvant Treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma Active, not recruiting NCT03529422 Phase 2 Durvalumab
41 M4OC-Prevent: Metformin for Oral Cancer Prevention Active, not recruiting NCT02581137 Phase 2 Metformin Hydrochloride
42 A Phase II Study of Sodium Thiosulfate (STS) for Prevention of Ototoxicity in Patients With Locally Advanced Squamous Cell Carcinoma of Head and Neck (SCCHN) Undergoing Concurrent Chemoradiation With Cisplatin Active, not recruiting NCT04541355 Phase 2 Cisplatin;Sodium Thiosulfate
43 Guided by Light: Optimizing Surgical Excision of Oral Cancer Using Real-time Fluorescence Imaging Not yet recruiting NCT04191460 Phase 2 cRGD-ZW800-1.
44 Therapeutic Efficacy of Quercetin Versus Its Encapsulated Nanoparticle on Tongue Squamous Cell Carcinoma Cell Line Not yet recruiting NCT05456022 Phase 2 Quercetin 3,3',4',5,6-Pentahydroxyflavone, 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one;Quercetin-encapsulated PLGA-PEG nanoparticles (Nano-QUT);Doxorubicin chemotherapeutic drug as a positive control
45 M4OC-Prevent 2.0: Phase IIb Trial of Metformin for Oral Cancer Prevention Not yet recruiting NCT05237960 Phase 2 Extended Release Metformin Hydrochloride;Placebo Administration
46 Intraoperative Visualization of Oral Cavity Squamous Cell Carcinoma and High-Grade Dysplasia With Tozuleristide, a Fluorescent Tumor Marking Agent Not yet recruiting NCT05316688 Phase 1, Phase 2 Tozuleristide
47 Phase II Study of Induction Docetaxel, Cisplatin and 5-Fluorouracil Chemotherapy in Squamous Cell Carcinoma of the Oral Cavity With Molecular Endpoints Terminated NCT00400205 Phase 2 Docetaxel;Cisplatin;5-fluorouracil
48 Evaluation of Polarized Reflectance Spectroscopy for Detection of High-risk Oral Lesions Completed NCT01604759 Phase 1
49 Phase I Study of Pre-operative Combination Therapy With Mogamulizumab (Anti-CCR4) and Nivolumab (Anti-PD-1) Against Solid Cancer Patients Completed NCT02946671 Phase 1
50 Phase I Study of Bortezomib and Cetuximab Without or With Cisplatin in Combination With Radiation Therapy for Advanced Head and Neck Cancer Completed NCT01445405 Phase 1 Bortezomib (Velcade, PS-341);Cetuximab;Cisplatin

Search NIH Clinical Center for Lip and Oral Cavity Cancer

Genetic Tests for Lip and Oral Cavity Cancer

Anatomical Context for Lip and Oral Cavity Cancer

Organs/tissues related to Lip and Oral Cavity Cancer:

MalaCards : Tongue, Lymph Node, Endothelial, Nk Cells, Bone, Breast, Myeloid

Publications for Lip and Oral Cavity Cancer

Articles related to Lip and Oral Cavity Cancer:

(show top 50) (show all 14123)
# Title Authors PMID Year
1
Multiple single nucleotide polymorphism analysis and association of specific genotypes in FHIT, SAMD4A, and ANKRD17 in Indian patients with oral cancer. 62 5
28580594 2017
2
Shiga Toxin-B Targeted Gold Nanorods for Local Photothermal Treatment in Oral Cancer Clinical Samples. 62 41
36466783 2022
3
Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. 62 46
20233326 2010
4
LINC00629, a KLF10-responsive lncRNA, promotes the anticancer effects of apigenin by decreasing Mcl1 stability in oral squamous cell carcinoma. 41
36445338 2022
5
Oral Lichen Planus and Oral Squamous Cell Carcinoma share key oncogenic signatures. 41
36450755 2022
6
Diagnostic clinical aids in oral cancer. 53 62
20371204 2010
7
Fatty-acid-binding protein 5 promotes cell proliferation and invasion in oral squamous cell carcinoma. 53 62
20040021 2010
8
Epidermal growth factor receptor regulates beta-catenin location, stability, and transcriptional activity in oral cancer. 53 62
20302655 2010
9
Transactivation and expression patterns of Jun and Fos/AP-1 super-family proteins in human oral cancer. 53 62
19653276 2010
10
[Expression of survivin, caspase-3 in oral precancerous lesions and oral squamous-cell carcinoma]. 53 62
20368001 2010
11
Detection of N-, H-, and KRAS codons 12, 13, and 61 mutations with universal RAS primer multiplex PCR and N-, H-, and KRAS-specific primer extension. 53 62
19879255 2010
12
KO-202125, a sauristolactam derivate, induces apoptosis to prevent KB human oral squamous carcinoma cells through inhibition of cyclooxygenase-2 expression. 53 62
19910795 2010
13
The association between hypoxia inducible factor-1alpha gene polymorphisms and increased susceptibility to oral cancer. 53 62
19717330 2009
14
S-allylcysteine modulates the expression of E-cadherin and inhibits the malignant progression of human oral cancer. 53 62
19157822 2009
15
Modulation of EGFR by oral squamous cell carcinoma cell lines. 53 62
20066875 2009
16
Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. 46
19776030 2009
17
Significance of promoter hypermethylation of p16 gene for margin assessment in carcinoma tongue. 53 62
19431196 2009
18
Evaluation of the cytotoxic and genotoxic effects of orthodontic bonding adhesives upon human gingival papillae through immunohistochemical expression of p53, p63 and p16. 53 62
19846940 2009
19
Study on TP53 codon 72 polymorphisms with oral carcinoma susceptibility. 53 62
20082880 2009
20
Protective role of Withaferin-A on immunoexpression of p53 and bcl-2 in 7,12-dimethylbenz(a)anthracene-induced experimental oral carcinogenesis. 53 62
19009234 2009
21
Role of nitric oxide and antioxidant enzymes in the pathogenesis of oral cancer. 53 62
20160357 2009
22
Contribution of genetic polymorphisms of stromal cell-derived factor-1 and its receptor, CXCR4, to the susceptibility and clinicopathologic development of oral cancer. 53 62
19373784 2009
23
Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer. 53 62
19204927 2009
24
CCL5/CCR5 axis promotes the motility of human oral cancer cells. 53 62
19334035 2009
25
Polymorphisms in the hypoxia inducible factor 1-alpha and the impact on the prognosis of early stages of oral cancer. 53 62
19449077 2009
26
Detection of survivin and p53 in human oral cancer: correlation with clinicopathologic findings. 53 62
19340865 2009
27
Overexpression of DPAGT1 leads to aberrant N-glycosylation of E-cadherin and cellular discohesion in oral cancer. 53 62
19549906 2009
28
RNAi targeting urokinase-type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo. 53 62
19391133 2009
29
Expression of Fas/FasL in patients with oral lichen planus. 53 62
19810143 2009
30
Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. 53 62
19525975 2009
31
Matrix metalloproteinases (MMP) 1 and MMP10 but not MMP12 are potential oral cancer markers. 53 62
19489686 2009
32
MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset. 53 62
18804411 2009
33
Ribonucleotide reductase small subunit p53R2 promotes oral cancer invasion via the E-cadherin/beta-catenin pathway. 53 62
18804405 2009
34
Expression of metallothionein and p53 antigens are correlated in oral squamous cell carcinoma. 53 62
19414363 2009
35
Pin1 overexpression is associated with poor differentiation and survival in oral squamous cell carcinoma. 53 62
19288014 2009
36
Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesions. 53 62
19197984 2009
37
Immunoexpression of cyclooxygenase-2 and p53 in oral squamous cell carcinoma. 53 62
19239949 2009
38
Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. 53 62
19276369 2009
39
E-Cadherin truncation and sialyl Lewis-X overexpression in oral squamous cell carcinoma and oral precancerous conditions. 53 62
19152244 2009
40
Expression of p16 in oral cancer and premalignant lesions. 53 62
19192055 2009
41
GSTM1, GSTT1 and CYP1A1 polymorphisms and risk of oral cancer: a case-control study in Jakarta, Indonesia. 53 62
19469619 2009
42
CYP1A1 and GSTM1 polymorphisms and oral cancer risk: association studies via evidence-based meta-analyses. 53 62
19160101 2009
43
Prevalence of CYP1A1 and GST polymorphisms in the population of northeastern India and susceptibility of oral cancer. 53 62
19718946 2009
44
Oral epithelial hyperplasia in diabetes mellitus. 53 62
20067171 2009
45
Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients. 53 62
19123955 2009
46
Telomere attrition and telomerase activity are associated with GSTM1 polymorphism in oral cancer. 53 62
19729828 2009
47
Effects of epidermal growth factor on the invasion activity of the oral cancer cell lines HSC3 and SAS. 53 62
18485796 2008
48
RNAi-mediated downregulation of urokinase plasminogen activator receptor inhibits proliferation, adhesion, migration and invasion in oral cancer cells. 53 62
18486529 2008
49
Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. 53 62
18701437 2008
50
Multiple aberrations of chromosome 3p detected in oral premalignant lesions. 53 62
19138989 2008

Variations for Lip and Oral Cavity Cancer

ClinVar genetic disease variations for Lip and Oral Cavity Cancer:

5 (show all 48)
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 GRIK2 NM_021956.5(GRIK2):c.2086-16819C>T SNV Association
252988 rs1335022 GRCh37: 6:102466397-102466397
GRCh38: 6:102018522-102018522
2 PREX2 NM_024870.4(PREX2):c.142-2489C>T SNV Association
252989 rs4512367 GRCh37: 8:68927592-68927592
GRCh38: 8:68015357-68015357
3 MMP2 NM_004530.5(MMP2):c.-1586C>T SNV Association
429032 rs243865 GRCh37: 16:55511806-55511806
GRCh38: 16:55477894-55477894
4 SNTB1 NM_021021.4(SNTB1):c.571+12964G>A SNV Association
430630 rs10090787 GRCh37: 8:121810549-121810549
GRCh38: 8:120798309-120798309
5 SAMD4A NM_015589.6(SAMD4A):c.1176+4220T>C SNV Association
430718 rs1957358 GRCh37: 14:55222475-55222475
GRCh38: 14:54755757-54755757
6 ANKRD17 NM_032217.5(ANKRD17):c.7731G>A (p.Thr2577=) SNV Association
430719 rs2306058 GRCh37: 4:73942678-73942678
GRCh38: 4:73076961-73076961
7 CNTN4 NM_175607.3(CNTN4):c.55+61947C>T SNV Association
430714 rs9849237 GRCh37: 3:2675189-2675189
GRCh38: 3:2633505-2633505
8 FHIT NM_002012.4(FHIT):c.104-196657C>A SNV Association
431027 rs11130760 GRCh37: 3:60196537-60196537
GRCh38: 3:60210809-60210809
9 LNX1 NM_001126328.3(LNX1):c.381-27505G>A SNV Association Not Found
619293 rs1435218 GRCh37: 4:54401899-54401899
GRCh38: 4:53535732-53535732
10 CCDC3 NM_031455.4(CCDC3):c.550-478A>G SNV Association Not Found
619294 rs4748011 GRCh37: 10:12941157-12941157
GRCh38: 10:12899157-12899157
11 RASGRP3 NM_170672.3(RASGRP3):c.-261+9727G>T SNV Association
236028 rs2124437 GRCh37: 2:33682737-33682737
GRCh38: 2:33457670-33457670
12 TP53 NM_000546.6(TP53):c.215C>G (p.Pro72Arg) SNV Pathogenic
12351 rs1042522 GRCh37: 17:7579472-7579472
GRCh38: 17:7676154-7676154
13 TP53 NM_000546.6(TP53):c.455C>T (p.Pro152Leu) SNV Pathogenic
142766 rs587782705 GRCh37: 17:7578475-7578475
GRCh38: 17:7675157-7675157
14 TP53 NM_000546.6(TP53):c.472C>T (p.Arg158Cys) SNV Pathogenic
127812 rs587780068 GRCh37: 17:7578458-7578458
GRCh38: 17:7675140-7675140
15 TP53 NM_000546.6(TP53):c.493C>T (p.Gln165Ter) SNV Pathogenic
182930 rs730882001 GRCh37: 17:7578437-7578437
GRCh38: 17:7675119-7675119
16 TP53 NM_000546.6(TP53):c.517G>A (p.Val173Met) SNV Pathogenic
233951 rs876660754 GRCh37: 17:7578413-7578413
GRCh38: 17:7675095-7675095
17 KIT NM_000222.3(KIT):c.1621A>C (p.Met541Leu) SNV Pathogenic
41599 rs3822214 GRCh37: 4:55593464-55593464
GRCh38: 4:54727298-54727298
18 STK11 NM_000455.5(STK11):c.1071G>T (p.Glu357Asp) SNV Pathogenic
412537 rs556651007 GRCh37: 19:1223134-1223134
GRCh38: 19:1223135-1223135
19 CDKN2A NM_000077.5(CDKN2A):c.238C>T (p.Arg80Ter) SNV Pathogenic
9409 rs121913388 GRCh37: 9:21971120-21971120
GRCh38: 9:21971121-21971121
20 TP53 NM_000546.6(TP53):c.524G>A (p.Arg175His) SNV Pathogenic
12374 rs28934578 GRCh37: 17:7578406-7578406
GRCh38: 17:7675088-7675088
21 CDKN2A NM_000077.5(CDKN2A):c.330G>A (p.Trp110Ter) SNV Pathogenic
376303 rs121913389 GRCh37: 9:21971028-21971028
GRCh38: 9:21971029-21971029
22 TP53 NM_000546.6(TP53):c.376-1G>A SNV Pathogenic
481003 rs868137297 GRCh37: 17:7578555-7578555
GRCh38: 17:7675237-7675237
23 TP53 NM_000546.6(TP53):c.743G>A (p.Arg248Gln) SNV Pathogenic
12356 rs11540652 GRCh37: 17:7577538-7577538
GRCh38: 17:7674220-7674220
24 TP53 NM_000546.6(TP53):c.638G>A (p.Arg213Gln) SNV Pathogenic
135359 rs587778720 GRCh37: 17:7578211-7578211
GRCh38: 17:7674893-7674893
25 TP53 NM_000546.6(TP53):c.722C>T (p.Ser241Phe) SNV Pathogenic
12359 rs28934573 GRCh37: 17:7577559-7577559
GRCh38: 17:7674241-7674241
26 TP53 NM_000546.6(TP53):c.742C>T (p.Arg248Trp) SNV Pathogenic
12347 rs121912651 GRCh37: 17:7577539-7577539
GRCh38: 17:7674221-7674221
27 TP53 NM_000546.6(TP53):c.731G>C (p.Gly244Ala) SNV Pathogenic
458560 rs985033810 GRCh37: 17:7577550-7577550
GRCh38: 17:7674232-7674232
28 TP53 NM_000546.6(TP53):c.799C>T (p.Arg267Trp) SNV Pathogenic
141764 rs55832599 GRCh37: 17:7577139-7577139
GRCh38: 17:7673821-7673821
29 TP53 NM_000546.6(TP53):c.820G>T (p.Val274Phe) SNV Pathogenic
376674 rs1057520005 GRCh37: 17:7577118-7577118
GRCh38: 17:7673800-7673800
30 TP53 NM_000546.6(TP53):c.821T>G (p.Val274Gly) SNV Pathogenic
376676 rs1057520006 GRCh37: 17:7577117-7577117
GRCh38: 17:7673799-7673799
31 ABL1 NM_005157.6(ABL1):c.764A>T (p.Glu255Val) SNV Pathogenic
376091 rs121913449 GRCh37: 9:133738364-133738364
GRCh38: 9:130862977-130862977
32 ABL1 NM_005157.6(ABL1):c.1187A>G (p.His396Arg) SNV Pathogenic
376097 rs121913454 GRCh37: 9:133750356-133750356
GRCh38: 9:130874969-130874969
33 HRAS, LRRC56 NM_005343.4(HRAS):c.182A>T (p.Gln61Leu) SNV Pathogenic
376033 rs121913233 GRCh37: 11:533874-533874
GRCh38: 11:533874-533874
34 PIK3CA NM_006218.4(PIK3CA):c.1625A>C (p.Glu542Ala) SNV Pathogenic
376473 rs1057519927 GRCh37: 3:178936083-178936083
GRCh38: 3:179218295-179218295
35 HRAS, LRRC56 NM_005343.4(HRAS):c.38G>T (p.Gly13Val) SNV Pathogenic
180848 rs104894226 GRCh37: 11:534285-534285
GRCh38: 11:534285-534285
36 RB1 NM_000321.3(RB1):c.2039T>C (p.Ile680Thr) SNV Pathogenic
977767 rs1949384455 GRCh37: 13:49033902-49033902
GRCh38: 13:48459766-48459766
37 TP53 NM_000546.6(TP53):c.610G>T (p.Glu204Ter) SNV Pathogenic
977783 rs2073336758 GRCh37: 17:7578239-7578239
GRCh38: 17:7674921-7674921
38 HRAS, LRRC56 NM_005343.4(HRAS):c.35G>A (p.Gly12Asp) SNV Pathogenic
12612 rs104894230 GRCh37: 11:534288-534288
GRCh38: 11:534288-534288
39 HRAS, LRRC56 NM_005343.4(HRAS):c.37G>C (p.Gly13Arg) SNV Pathogenic
35554 rs104894228 GRCh37: 11:534286-534286
GRCh38: 11:534286-534286
40 HRAS, LRRC56 NM_005343.4(HRAS):c.181C>A (p.Gln61Lys) SNV Pathogenic
12601 rs28933406 GRCh37: 11:533875-533875
GRCh38: 11:533875-533875
41 TP53 NM_000546.6(TP53):c.916C>T (p.Arg306Ter) SNV Pathogenic
142144 rs121913344 GRCh37: 17:7577022-7577022
GRCh38: 17:7673704-7673704
42 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg) SNV Pathogenic
13652 rs121913279 GRCh37: 3:178952085-178952085
GRCh38: 3:179234297-179234297
43 PIK3CA NM_006218.4(PIK3CA):c.1624G>A (p.Glu542Lys) SNV Pathogenic
31944 rs121913273 GRCh37: 3:178936082-178936082
GRCh38: 3:179218294-179218294
44 HRAS, LRRC56 NM_005343.4(HRAS):c.34G>A (p.Gly12Ser) SNV Pathogenic
12602 rs104894229 GRCh37: 11:534289-534289
GRCh38: 11:534289-534289
45 BRAF NM_004333.6(BRAF):c.1277G>C (p.Arg426Thr) SNV Pathogenic
977765 rs1801030116 GRCh37: 7:140482858-140482858
GRCh38: 7:140783058-140783058
46 CDKN2A NM_000077.5(CDKN2A):c.233_234del (p.Leu78fs) MICROSAT Likely Pathogenic
977782 rs1819713922 GRCh37: 9:21971124-21971125
GRCh38: 9:21971125-21971126
47 EGFR NM_005228.5(EGFR):c.2235_2237del (p.Glu746del) DEL Likely Pathogenic
977766 rs1786518484 GRCh37: 7:55242464-55242466
GRCh38: 7:55174771-55174773
48 TP53 NM_000546.6(TP53):c.902del (p.Pro301fs) DEL Likely Pathogenic
233908 rs876660726 GRCh37: 17:7577036-7577036
GRCh38: 17:7673718-7673718

Copy number variations for Lip and Oral Cavity Cancer from CNVD:

6 (show top 50) (show all 92)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 16000 1 120982663 144003083 Loss Oral cancer
2 18683 1 147134204 147499075 Loss Oral cancer
3 22566 1 167493797 167507911 Loss NME7 Oral cancer
4 25915 1 195026732 195048237 Gain Oral cancer
5 25916 1 195026732 195104236 Gain Oral cancer
6 30920 1 246713386 246852155 Loss Oral cancer
7 35162 1 604268 4312064 Gain Oral cancer
8 41154 10 138235 42150788 Loss Oral cancer
9 42635 10 37475290 37508431 Loss Oral cancer
10 43408 10 46396192 46516611 Loss Oral cancer
11 48616 11 101407278 102165885 Gain Oral cancer
12 49060 11 102611683 110151240 Loss Oral cancer
13 50726 11 119044645 133316524 Loss Oral cancer
14 52672 11 186966 2789993 Gain Oral cancer
15 55431 11 52900000 134452384 Gain Oral cancer
16 56752 11 60970713 78077527 Gain Oral cancer
17 58595 11 68654476 70150073 Gain Oral cancer
18 79103 13 6365 44752 Loss Oral cancer
19 82813 14 15600000 106368585 Gain Oral cancer
20 83220 14 19560721 22142166 Gain Oral cancer
21 83591 14 21538460 22005864 Gain Oral cancer
22 85535 14 48265939 80627188 Gain Oral cancer
23 88199 14 87604117 106349785 Gain Oral cancer
24 89600 15 18741744 19805989 Loss Oral cancer
25 89601 15 18741744 20060090 Gain Oral cancer
26 101423 16 36766 2592859 Gain Oral cancer
27 106087 16 85963377 88690615 Gain Oral cancer
28 118416 17 77385789 78462808 Gain Oral cancer
29 120365 18 24990733 76110993 Loss Oral cancer
30 124096 19 1 28500000 Gain Oral cancer
31 127007 19 232109 258746 Gain Oral cancer
32 133960 19 8275 236875 Loss Oral cancer
33 136827 2 133504494 133812256 Loss NCKAP5 Oral cancer
34 144179 2 242501268 242717042 Gain Oral cancer
35 150414 20 1 27100000 Gain Oral cancer
36 151218 20 18609 5869816 Gain Oral cancer
37 151741 20 24728423 25680524 Gain Oral cancer
38 152139 20 29436566 62363603 Gain Oral cancer
39 155361 20 55096989 59483462 Gain Oral cancer
40 155973 20 59483462 62194881 Gain Oral cancer
41 160312 22 134684 14797037 Loss Oral cancer
42 164561 22 37689087 37715408 Loss Oral cancer
43 166146 3 1 91700000 Deletion Oral cancer
44 166162 3 1 91700000 Loss Oral cancer
45 167591 3 121355348 144551988 Gain Oral cancer
46 169747 3 145187343 199379595 Gain Oral cancer
47 171086 3 163941201 164138371 Loss Oral cancer
48 172647 3 185019156 185896384 Gain Oral cancer
49 175342 3 39095 9150490 Loss CHL1 Oral cancer
50 175343 3 39095 9150490 Loss GRM7 Oral cancer

Expression for Lip and Oral Cavity Cancer

Search GEO for disease gene expression data for Lip and Oral Cavity Cancer.

Pathways for Lip and Oral Cavity Cancer

Pathways related to Lip and Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 84)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.83 TP53 RB1 PIK3CA KIT HRAS EGFR
2 13.8 TP53 STK11 RARB PIK3CA KIT HRAS
3
Show member pathways
13.8 ABL1 BRAF CCND1 CDKN2A EGFR HRAS
4
Show member pathways
13.73 TP53 RB1 KIT HRAS EGFR CDKN2A
5
Show member pathways
13.49 ABL1 BRAF CCND1 CDKN2A EGFR HRAS
6
Show member pathways
12.97 CCND1 EGFR HRAS KIT PIK3CA STK11
7
Show member pathways
12.88 BRAF CCND1 HRAS PIK3CA TP53
8 12.87 PIK3CA KIT HRAS EGFR BRAF
9
Show member pathways
12.87 PIK3CA KIT HRAS EGFR BRAF
10
Show member pathways
12.7 TP53 RB1 HRAS EGFR BRAF
11 12.67 TP53 PIK3CA KIT HRAS EGFR CDKN2A
12
Show member pathways
12.56 TP53 RB1 RARB PIK3CA KIT HRAS
13
Show member pathways
12.53 RB1 CDKN2A CCND1 ABL1
14
Show member pathways
12.53 TP53 PIK3CA HRAS EGFR BRAF
15
Show member pathways
12.51 RB1 CDKN2A CCND1 ABL1
16
Show member pathways
12.5 BRAF CCND1 HRAS PIK3CA TP53
17
Show member pathways
12.47 TP53 PIK3CA HRAS EGFR
18
Show member pathways
12.47 BRAF CCND1 CDKN2A EGFR HRAS KIT
19
Show member pathways
12.45 PIK3CA HRAS EGFR CCND1
20 12.44 BRAF EGFR HRAS TP53
21
Show member pathways
12.43 PIK3CA KIT HRAS EGFR BRAF
22
Show member pathways
12.36 PIK3CA HRAS EGFR CCND1
23 12.32 PIK3CA HRAS EGFR CCND1 BRAF
24
Show member pathways
12.31 PIK3CA EGFR BRAF ABL1
25
Show member pathways
12.3 TP53 PIK3CA HRAS CCND1
26 12.29 KRT13 CYP1A1 CDKN2A CCND1
27
Show member pathways
12.29 TP53 RB1 PIK3CA KIT HRAS EGFR
28
Show member pathways
12.27 PIK3CA HRAS EGFR CCND1
29
Show member pathways
12.27 TP53 RB1 CDKN2A CCND1 ABL1
30 12.27 PIK3CA KIT HRAS EGFR ABL1
31
Show member pathways
12.25 TP53 RB1 CCND1 ABL1
32 12.23 TP53 EGFR CCND1 BRAF
33
Show member pathways
12.17 PIK3CA HRAS EGFR CCND1
34
Show member pathways
12.16 HRAS PIK3CA STK11 TP53
35
Show member pathways
12.15 TP53 RB1 CCND1 ABL1
36
Show member pathways
12.15 TP53 RB1 CDKN2A CCND1
37
Show member pathways
12.15 TP53 PIK3CA HRAS CDKN2A CCND1
38 12.13 BRAF EGFR STK11 TP53
39
Show member pathways
12.13 BRAF CCND1 EGFR HRAS PIK3CA RB1
40
Show member pathways
12.06 TP53 PIK3CA EGFR BRAF
41 12.04 TP53 STK11 RB1 EGFR CCND1 BRAF
42 12.03 TP53 RB1 EGFR CCND1
43 11.96 TP53 RB1 HRAS CDKN2A BRAF
44 11.93 TP53 PIK3CA HRAS CCND1 ABL1
45
Show member pathways
11.89 KIT EGFR CCND1
46 11.89 PIK3CA KIT HRAS EGFR CDKN2A CCND1
47 11.87 TP53 RB1 CCND1 ABL1
48 11.87 CCND1 PIK3CA RARB RB1 TP53
49 11.85 HRAS PIK3CA TP53
50 11.84 KIT GSTM1 CDKN2A CCND1

GO Terms for Lip and Oral Cavity Cancer

Biological processes related to Lip and Oral Cavity Cancer according to GeneCards Suite gene sharing:

(show all 26)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell population proliferation GO:0008285 10.27 TP53 STK11 RB1 MIR21 HRAS CDKN2A
2 positive regulation of gene expression GO:0010628 10.23 TP53 MIR21 KIT HRAS CDKN2A BRAF
3 negative regulation of gene expression GO:0010629 10.21 TP53 RB1 PIK3CA MIR21 HRAS
4 negative regulation of neuron apoptotic process GO:0043524 10.21 BRAF CCND1 HRAS PIK3CA
5 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.21 ABL1 BRAF EGFR HRAS MIR21
6 cell cycle GO:0007049 10.2 TP53 STK11 RB1 CDKN2A CDK2AP1 CCND1
7 negative regulation of cell growth GO:0030308 10.19 CDKN2A RB1 STK11 TP53
8 Ras protein signal transduction GO:0007265 10.1 TP53 RB1 HRAS CDKN2A
9 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 10.07 EGFR CYP1A1 CCND1
10 T cell receptor signaling pathway GO:0050852 10.07 ABL1 BRAF HRAS PIK3CA STK11
11 cellular senescence GO:0090398 10.06 ABL1 CDKN2A HRAS TP53
12 phosphorylation GO:0016310 10.03 STK11 PIK3CA KIT EGFR CDKN2A BRAF
13 digestive tract development GO:0048565 10.01 RB1 KIT CYP1A1
14 epidermal growth factor receptor signaling pathway GO:0007173 10.01 PIK3CA EGFR BRAF ABL1
15 regulation of cell population proliferation GO:0042127 9.97 TP53 KIT HRAS EGFR BRAF ABL1
16 regulation of cell cycle GO:0051726 9.97 ABL1 CCND1 CDKN2A HRAS RB1 STK11
17 cellular response to gamma radiation GO:0071480 9.95 TP53 MIR21 HRAS
18 myeloid progenitor cell differentiation GO:0002318 9.92 KIT BRAF
19 positive regulation of extracellular matrix organization GO:1903055 9.87 RB1 ABL1
20 response to UV-A GO:0070141 9.83 CCND1 EGFR
21 positive regulation of protein phosphorylation GO:0001934 9.73 MIR21 HRAS EGFR CDK2AP1 CCND1 BRAF
22 positive regulation of vascular associated smooth muscle cell differentiation GO:1905065 9.69 KIT MIR21
23 programmed cell death GO:0012501 9.65 TP53 RARB KIT
24 negative regulation of mitotic cell cycle GO:0045930 9.65 TP53 RB1 MIR21 ABL1
25 positive regulation of miRNA maturation GO:1903800 9.62 TP53 EGFR
26 cell population proliferation GO:0008283 9.23 TP53 RB1 RARB KIT EGFR CYP1A1

Molecular functions related to Lip and Oral Cavity Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 enzyme binding GO:0019899 9.9 CCND1 CYP1A1 EGFR GSTM1 RB1 TP53
2 protein tyrosine kinase activity GO:0004713 9.87 KIT EGFR BRAF ABL1
3 disordered domain specific binding GO:0097718 9.65 TP53 RB1 CDKN2A
4 protein kinase activity GO:0004672 9.61 STK11 KIT EGFR CCND1 BRAF ABL1
5 kinase activity GO:0016301 9.32 STK11 PIK3CA KIT EGFR CDKN2A CCND1

Sources for Lip and Oral Cavity Cancer

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....